Latest Development Pipeline News

HomeCo Daily Needs REIT has reported steady growth in funds from operations for the first half of FY26, supported by strong asset valuations and operational metrics, while reaffirming its full-year guidance.

Stellar Resources has completed the acquisition of the Granite Tor Tin Project, significantly expanding its presence in Tasmania’s renowned tin province and reinforcing its development pipeline alongside the Heemskirk Project.

Dexus Convenience Retail REIT has reported solid half-year results for 2026, underpinned by resilient income growth and a $19.8 million uplift in portfolio valuation. The fund maintains a conservative capital structure while advancing key development projects.

Dexus Convenience Retail REIT (DXC) reports solid HY26 results with strong income growth and high occupancy, while advancing strategic development projects to enhance its metro and highway retail footprint.

Dexus Convenience Retail REIT has reported a striking 143.8% increase in net profit for the half-year to December 2025, underpinned by strong portfolio occupancy and rising property valuations. The REIT reaffirmed its FY26 guidance, signalling confidence in its defensive income strategy and development pipeline.

HMC Capital has forged a strategic partnership with global investor KKR, securing up to $603 million to expand its Energy Transition Platform focused on battery storage and wind projects. This deal aims to boost Australia’s renewable capacity while enhancing shareholder returns.

Great Divide Mining has raised $2.5 million through a share placement to fund development at its Challenger Gold Mine and progress other key projects.

Everlast Minerals has secured a significant new exploration licence in northern Bangladesh, boosting its mineral sands portfolio and advancing its development strategy.

Delorean Corporation has completed the $53 million Yarra Valley Water bioenergy facility and progressed key projects in South Australia and Victoria, supported by strong government grants and renewable gas policies.

Biotron Limited has successfully closed its fully subscribed rights issue, raising $1.52 million, and completed the acquisition of Sedarex Limited, positioning itself for growth in its diversified biotech portfolio.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.